Effects of human low-density lipoproteins on superoxide production by formyl-methionyl-leucyl-phenylalanine activated polymorphonuclear leukocytes

European Journal of Clinical Chemistry and Clinical Biochemistry

Volumn 35, Issue 2, 1997, Pages 73-80

  Bonneau, Christine ^a,b,c   Couderc, Rémy ^a   Tissot, Michéle ^a   Athias, Anne ^a   Roch Arveiller, Monique ^a   Giroud, Jean Paul ^a  

^a Laboratoire de Pharmacologie Unité CNRS 15 35 Hôpital Cochin ^*  (France)

^b HÔPITAL DU BOCAGE   (France)

^c HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NIFLUMIC ACID; PERTUSSIS TOXIN; PHOSPHATIDYLINOSITIDE; PHOSPHOLIPASE A2; PHOSPHOLIPASE D; PROPRANOLOL; STAUROSPORINE; SUPEROXIDE;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL DAMAGE; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; MEMBRANE FLUIDITY; NEUTROPHIL; NORMAL HUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RESPIRATORY BURST;

EID: 0030932330     PISSN: 09394974     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoproteins that increase its atherogenicity. N Engl J Med 1989; 320:915-24.
2. Slyper AH. Low-density lipoprotein density and atherosclerosis. J Am Med Ass 1994; 272:305-8.
3. Terkeltaub R, Curtiss LK, Tenner AJ, Ginsberg MH. Lipoproteins containing apoprotein B are a major regulator of neutrophil responses to monosodium urate crystals. J Clin Invest 1984; 73:1719-30.
4. Ludwig P, Hunninghake D, Hoidal J. Increased leukocyte oxidative metabolism in hyperlipoproteinaemia. Lancet 1982; 14:348-50.
5. Bonneau C, Couderc R, Roch-Arveiller M, Giroud JP, Raichvarg D. Effects of low-density lipoproteins on polymorphonuclear leukocyte functions in vitro. J Lipid Mediat Cell Signal 1994; 10:203-12.
6. Ricevuti G, Mazzone A, Pasotti D, De Servi S, Speccia G. Role of granulocytes in endothelial injury in coronary heart disease in humans. Atherosclerosis 1991; 91:1-14.
7. Harats D, Mulkins MA, Sigal E. A possible role for 15-lipoxygenase in atherogenesis. Trends Cardiovasc Med 1995; 5:29-36.
8. Consigny PM. Pathogenesis of atherosclerosis. Am J Roentgenol 1995; 164:553-8.
9. Ward PA. Mechanisms of endothelial cell injury. J Lab Clin Med 1991; 188:421-6.
10. Natarajan V. Oxidants and signal transduction in vascular endothelium. J Lab Clin Med 1995; 125:26-37.
11. Wieland E, Brandes A, Armstrong VW, Oellerich M. Oxidative modification of low-density lipoproteins by human polymorphonuclear leukocytes. Eur J Clin Chem Clin Biochem 1993; 31:725-31.
12. Jackson RL, Ku G, Thomas CE. Antioxydants: a biological defense mechanism for the prevention of atherosclerosis. Med Res Rev 1993; 13:161-82.
13. Kilgore KS, Lucchesi BR. Reperfusion injury after myocardial infarction: the role of free radicals and the inflammatory response. Clin Biochem 1993; 26:359-70.
14. Babior BM. The respiratory burst of phagocytes. J Clin Invest 1984; 73:599-601.
15. Chanock SJ, El Benna J, Smith RM, Babior BM. The respiratory burst oxidase. J Biol Chem 1994; 269:24519-22.
16. ++, and protein kinase C. J Bioenerg Biomembr 1988; 20:709-33.
17. Snyderman R, Uhig RJ. Phagocytic cells: stimulus-response coupling mechanisms. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: basic principles and clinical correlates. New York: Raven Press, 1988:309-23.
18. 2-mediated signalling in neutrophils. Biochim Biophys Acta 1992; 1113:135-60.
19. Baggiolini M, Boulay F, Badwey JA, Cumutte JT. Activation of neutrophil leukocytes: chemoattractant receptors and respiratory burst. FASEB J 1993; 7:1004-10.
20. Weingarten R, Bokoch GM. GTP binding proteins and signal transduction in the human neutrophil. Immunol Lett 1990; 26:1-6.
21. Thelen M, Dewald B, Baggiolini M. Neutrophil signal transduction and activation of the respiratory burst. Physiol Rev 1993; 73:797-821.
22. Zenou M, Raichvarg D, Agneray J. Unmodified phagocytosis after periodate treatment of human granulocytes separated by a two-step method using Ficoll-Hypaque and polyvinylic alcohol medium. Biomedicine 1981; 35:166-9.
23. Johnston RB, Keel BB, Misra HP, Lehmeyer JE, Webb LS, Baehner RL, et al. The role of Superoxide anion generation in phagocytic bactericidal activity. J Clin Invest 1975; 55:1357-72.
24. Tissot M, Mathieu J, Mirossay L, Thuret A, Giroud JP. Polyphosphoinositide metabolism in polymorphonuclear cells from healthy and thermally injured rats. Effect of the immunomodulator RU 41740. J Leukoc Biol 1991; 50:607-14.
25. 2+-mobilizing hormones. Biochem J 1983; 212:733-47.
26. + + influx and polyphosphoinositide metabolism in isolated rat hepatocytes. Biochem J 1986; 235:663-9.
27. Downes CP, Michell RH. The polyphosphoinositide phosphodiesterase of erythrocyte membranes. Biochem J 1981; 198:133-40.
28. Berridge MJ, Dawson RMC, Downes CP, Heslop JP, Irvine RF. Changes in the levels of inositol phosphates after agonistdependent hydrolysis of membrane phosphoinositides. Biochem J 1983; 212:473-82.
29. Periani A, Snyderman R. Analysis of calcium homeostasis in activated human polymorphonuclear leucocytes: evidence for two distinct mechanisms for cytosolic calcium. J Biol Chem 1989; 264:1005-9.
30. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260:3440-50.
31. Kopf GS, Woolkalis MJ. ADP-ribosylation of G proteins with pertussis toxin. Methods Enzymol 1991; 195:257-66.
32. Gabig TG, English D, Akard LP, Schell MJ. Regulation of neutrophil NADPH oxidase activation in a cell-free system by guanine nucleotides and fluoride. J Biol Chem 1987; 262:1685-90.
33. Omann GM, Porasik-Lowes MM. Graded G-protein uncoupling by pertussis toxin treatment of human polymorphonuclear leukocytes. J Immunol 1991; 146:1303-8.
34. Hallet MB, Lloyds D. Neutrophil priming: the cellular signals that say 'amber' but not 'green'. Immunol Today 1995; 16:264-8.
35. Block LH, Knorr M, Vogt E, Locher R, Vetter W, Groscurth P, et al. Low density lipoprotein causes general cellular activation with increased phosphatidylinositol turnover and lipoprotein catabolism. Proc Natl Acad Sci USA 1988; 85:885-9.
36. ++ dependent protein kinase. Biochem Biophys Res Commun 1986; 135:397-402.
37. Nakadate T, Yeng AY, Blumberg PM. Comparison of protein kinase C functional assays to clarify mechanisms of inhibitor action. Biochem Pharmac 1988; 37:1541-5.
38. Blumberg PM. Complexities of the protein kinase C pathway. Mol Carcinog 1991; 4:339-44.
39. Badwey JA, Erickson RW, Curnutte JT. Staurosporine inhibits the soluble and membrane-bound protein tyrosine kinases of human neutrophils. Biochem Biophys Res Commun 1991; 178:423-9.
40. Combadiere C, Hakim J, Giroud JP, Perianin A. Staurosporine, a protein kinase inhibitor, up-regulates the stimulation of human neutrophil respiratory burst by N-formyl peptides and platelet activating factor. Biochem Biophys Res Commun 1990; 168: 65-70.
41. Combadiere C, El Benna J, Pedruzzi E, Hakim J, Perianin A. Stimulation of the human neutrophil respiratory burst by formyl peptides is primed by a protein kinase inhibitor, Staurosporine. Blood 1993; 82:2890-8.
42. Reinhold SL, Prescott SM, Zimmerman GA, Me Intyre TM. Activation of human neutrophil phospholipase D by three separable mechanisms. FASEB J 1990; 4:208-14.
43. Perianin A, Combadiere C, Pedruzzi E, Djerdjouri B, Hakim J. Staurosporine stimulates phospholipase D activation in human polymorphonuclear leukocytes. FEBS Lett 1993; 315:33-7.
44. Mori T, Ando M, Takagi K. Staurosporine and its derivatives enhance f-Met-Phe-induced Superoxide production via phospholipase D activation in human polymorphonuclear leukocytes. Int J Clin Pharmacol Ther 1994; 32:422-8.
45. Rossi F, Grzeskowiak M, Delia Bianca V, Calzetti F, Gandini G. Phosphatidic acid and not diacylglycerol generated by phospholipase D is functionally linked to the activation of the NADPH oxidase by fMLP in human neutrophils. Biochem Biophys Res Commun 1990; 168:320-7.
46. English D, Taylor GS. Divergent effects of propranolol on neutrophil superoxide release: involvement of phosphatidic acid and diacylglycerol as second messengers. Biochem Biophys Res Commun 1991; 175:423-9.
47. Agwu DE, Me Phail LC, Sozzani S, Bass DA, Me Call CE. Phosphatidic acid as a second messenger in human polymorphonuclear leukocytes. Effects on activation of NADPH oxidase. J Clin Invest 1991; 88:531-9.
48. Müller S, Nigam S. Arachidonic acid release and platelet-activating factor formation by staurosporine in human neutrophils challenged with n-formyl peptide. Eur J Pharmcol 1992; 218:251-8.
49. Abramson SB, Leszczynska-Piziak J, Weissman G. Arachidonic acid as a second messenger. Interactions with a GTPbinding protein of human neutrophils. J Immunol 1991; 147:231-6.
50. Bonneau C, Couderc R, Chanu B, Bailleul S, Roch-Arveiller M, Rouffy J, et al. Fonctions des polynucléaires neutrophiles de sujets hypercholestérolémiques. In: Galteau MM, Siest G, Henny J, editors. Biologie Prospective. Comptes rendus du Sème colloque de Pont-à-Mousson. Paris: John Libbey Eurotext, 1993:549-52.
51. Muller WA. Migration of leukocytes across the vascular intima. Molecules and mechanisms. Trends Cardiovas Med 1995; 5:15-20.
52. Kovanen PT. Atheroma formation: defective control in the intimai round-trip of cholesterol. Eur Heart J 1990; 11 (Suppl E):238-46.
53. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulation of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986; 6:131-8.
54. Kling D, Holzschuh T, Betz E. Recruitment and dynamics of leukocytes in the formation of arterial thickening - a comparative study with normo- and hypercholesterolemic rabbits. Atherosclerosis 1993; 101:79-96.